123
Participants
Start Date
August 31, 2016
Primary Completion Date
November 20, 2018
Study Completion Date
November 20, 2018
VX-371
Hypertonic Saline
Placebo (0.17% saline)
VX-371 + HS
Ivacaftor
Birmingham
Palo Alto
Aurora
Washington D.C.
Miami
Tampa
Chicago
Indianapolis
Iowa City
Kansas City
Boston
Ann Arbor
Minneapolis
Kansas City
St Louis
New York
Chapel Hill
Cleveland
Philadelphia
Columbia
Seattle
Toronto
Montreal
Copenhagen
Münster
Hanover
Heidelberg
Pisa
Amsterdam
Rotterdam
Rabka-Zdrój
Cambridge
London
Southampton
Lead Sponsor
Vertex Pharmaceuticals Incorporated
INDUSTRY
Parion Sciences
INDUSTRY